[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625541":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":64,"collaborators":30,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":30,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":92,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"High-dose Anakinra+standard medical treatment","EXPERIMENTAL","100 mg loading dose Anakinra over 60 seconds within 0.5 hours after randomization, followed by consecutive 2mg\u002Fkg\u002Fh infusions over 24 hours. Standard treatment strategy will be in the discretion of site investigators according to guidelines.",[13],"Drug: High-dose Anakinra",{"label":15,"type":10,"description":16,"interventionNames":17},"Low-dose Anakinra+standard medical treatment","100 mg subcutaneous Anakinra over 60 seconds within 0.5 hours after randomization, followed by 100 mg administered twice daily for 3 days. Standard treatment strategy will be in the discretion of site investigators according to guidelines.",[18],"Drug: Low-dose Anakinra",{"label":20,"type":6,"description":21,"interventionNames":22},"Standard medical treatment","All enrolled patients receive standard early management and secondary prevention treatment according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.",[23],"Other: Standard medical treatment",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","High-dose Anakinra","100 mg loading dose Anakinra over 60 seconds within 0.5 hours after randomization, followed by consecutive 2 mg\u002Fkg\u002Fh infusions over 24 hours.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Low-dose Anakinra","100 mg subcutaneous Anakinra over 60 seconds within 0.5 hours after randomization, followed by 100 mg administered twice daily for 3 days.",[15],{"type":6,"name":20,"description":36,"armGroupLabels":37,"otherNames":30},"Administration of standard medical treatment should be done according to routine clinical practice and current international guidelines.",[20],[39],{"name":40,"affiliation":5,"role":41},"Yunyun Xiong","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":30,"email":47},"Yunyun Xiong, professor","CONTACT","86-10-59978350","xiongyunyun@bjtth.org",[49],{"facility":50,"status":30,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Beijing tiantan hospital","Beijing","Beijing Municipality","100070","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":44,"role":45,"phone":46,"phoneExt":30,"email":47},{"type":41,"investigatorFullName":40,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Professor","100625541","phase-2-advancing-reperfusion-therapy-for-ischemic-stroke-safety-and-efficacy-of-anakinra-for-futile-reperfusion-following-endovascular-treatment-in-patients-with-acute-ischemic-stroke-100625541",false,"NCT07423975","Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)","ARTS-SAFE","Inclusion Criteria:\n\n* Age between 18-80 years old (both inclusive);\n* Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n* Pre-stroke modified Rankin scale (mRS) score ≤1;\n* Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (both inclusive);\n* Internal carotid artery (ICA) or middle cerebral artery (MCA) M1\u002FM2 occlusions confirmed by CTA\u002FMRA and responsible for the signs and symptoms of acute ischemic stroke;\n* Successful recanalization (eTICI 2b50-3) after endovascular treatment;\n* Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n* Allergy to Anakinra;\n* NIHSS consciousness score 1a \\>2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological\u002Fmental illness such that the patient is not able to cooperate or unwilling to cooperate;\n* Unable to perform CTP or PWI;\n* Acute or past intracerebral hemorrhage (ICH) (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hematoma) confirmed by CT or MRI;\n* Multiple arterial occlusion (e.g., bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);\n* Glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine level \\>2.5 mg\u002FdL;\n* Suspected septic embolism or infective endocarditis;\n* Neutropenia (ANC \\\u003C1.5 × 109\u002FL);\n* Known active or recurrent liver disease (including cirrhosis, hepatitis B and C; positive or indeterminate laboratory results), or alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) levels \\>3 times the upper limit of normal (ULN) or total bilirubin \\>2 times ULN;\n* History of malignancy other than basal cell carcinoma of the skin;\n* History or evidence of active or latent tuberculosis infection, or presence of tuberculosis risk factors including but not limited to: close contact with active tuberculosis patients within the past 12 months;\n* Any terminal illness such that the patient would not be expected to survive more than 1 year;\n* Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;\n* Unlikely to adhere to the trial protocol or follow-up;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n* Participation in other interventional clinical trials within the previous 3 months.","ALL","18 Years","80 Years",{"count":78,"type":79},159,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.",[85,86],"Stroke Acute","Endovascular Treatment",[88,89,90,91],"acute ischemic stroke","endovascular treatment","successful recanalization","Anakinra","NOT_YET_RECRUITING","2026-02-14",{"date":95,"type":96},"2026-02-20","ACTUAL",{"date":98,"type":79},"2026-03-01",{"date":100,"type":79},"2026-12-31",{"name":5,"class":6},1]